Citi, Neutral Medicine (PRME) is neutral, to $ 1.50 for the price of PT

Tuesday, Citi Downgred Pim Medicine Inc (NASDAQ:PRME) Significantly reduces the price target to a neutral rating of a purchase and significantly to $ 1.50. Citi said that this regulation is approaching the company’s shares in cash, and trades near those who show the uncertainty of the potential of the market in the potential value of the market.

One scientist is investigating a microbch and circuit board in a high-tech laboratory.

Although 25% of the workforce reduction and liver disease franchise and chronic granulomatosis, foreign financing programs, the maintenance of cash resources supported by the management of the management of the management of the management of the management of the management of the management of the management of the management and Alpha-1 for Alpha-1 Antitrypsin Deficiency / AATD 2027 aatd in a year. The company also plans to provide a new medication / ind relevant research for these programs in H1 2026 and 2026.

The chief medicine is looking for business development deals to ensure unwilling capital and expand the financial launching strip. Continuing the cynistics fibrosis program supported by the Cistored Fibrosis Foundation, and Bristol Myers cooperates with Squibb in hematology, immunology, immunology and Squibb of Bristol Myers in the Oncology. Prime Medicine Inc. (NASDAQ: PRME) is a biotechnic company that gives genetic therapy to solve the spectrum of diseases by placing Gene regulatory technology in the United States.

When we recognize the potential of PME, our beliefs are in the belief that some AI shares are giving higher income and a limited number of risks. If you are looking for a EU reserve with more promising and 100x upsideotal potential than PRME, review our report Cheap EU reserves.

Read the next: 30 shares of double in 3 years and Currently 8 secret EU reserves.

Disclosure: No. This article was first published Insayer monkey.